Alpha 2.0
Login Register
» Authors » Esther Kissling

Esther Kissling

Explore the profile of Esther Kissling including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 55
Citations 867
Followers 0
Related Specialties
Infectious Diseases
Microbiology
Allergy & Immunology
Top 10 Co-Authors
Marta Valenciano
Ausenda Machado
Adam Meijer
Ivan Martinez-Baz
Mihaela Lazar
Francisco Pozo
Joan ODonnell
Jesus Castilla
Lisa Domegan
Clara Mazagatos
Published In
Euro Surveill
Influenza Other Respir Viruses
Vaccine
Emerg Infect Dis
PLoS One
Affiliations
Soon will be listed here.
Recent Articles
1.
COVID-19 vaccine effectiveness in the paediatric population aged 5-17 years: a multicentre cohort study using electronic health registries in six European countries, 2021 to 2022
Soares P, Machado A, Nicolay N, Monge S, Sacco C, Holm Hansen C, et al.
Euro Surveill . 2025 Feb; 30(8). PMID: 40017392
BackgroundDuring the first year of the COVID-19 pandemic, vaccination programmes targeted children and adolescents to prevent severe outcomes of SARS-CoV-2 infection.AimTo estimate COVID-19 vaccine effectiveness (VE) against hospitalisation due to...
2.
Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025
Rose A, Lucaccioni H, Marsh K, Kirsebom F, Whitaker H, Emborg H, et al.
Euro Surveill . 2025 Feb; 30(7). PMID: 39980423
The 2024/25 influenza season in Europe is currently characterised by co-circulation of influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses, with influenza A(H1N1)pdm09 predominating. Interim vaccine effectiveness (VE) estimates from eight European...
3.
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024
Merdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, ODonnell J, Seve N, et al.
Influenza Other Respir Viruses . 2024 Nov; 18(11):e70009. PMID: 39523781
We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at...
4.
Primary series COVID-19 vaccine effectiveness among health care workers in the country of Georgia, March-December 2021
Katz M, Rojas Castro M, Chakhunashvili G, Chitadze N, Ward C, McKnight C, et al.
PLoS One . 2024 Sep; 19(9):e0307805. PMID: 39240827
Background: Healthcare workers (HCWs) have suffered considerable morbidity and mortality during the COVID-19 pandemic. Few data on COVID-19 vaccine effectiveness (VE) are available from middle-income countries in the WHO European...
5.
Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)]
Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, ODonnell J, et al.
Vaccine . 2024 Jul; 42(23):126089. PMID: 38971666
No abstract available.
6.
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans
Laniece Delaunay C, Mazagatos C, Martinez-Baz I, Turi G, Goerlitz L, Domegan L, et al.
JAMA Netw Open . 2024 Jul; 7(7):e2419258. PMID: 38949812
Importance: In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) to inform vaccination campaigns. Objective: To estimate...
7.
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024
Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, ODonnell J, et al.
Vaccine . 2024 Jun; 42(19):3931-3937. PMID: 38839521
In autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine. In a European multicentre study, we estimated 2023 COVID-19 vaccine effectiveness (VE) against laboratory-confirmed symptomatic infection at primary care level...
8.
Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe
Maurel M, Mazagatos C, Goerlitz L, Oroszi B, Hooiveld M, Machado A, et al.
Vaccine . 2024 May; 42(16):3547-3554. PMID: 38704257
Background: Within influenza vaccine effectiveness (VE) studies at primary care level with a laboratory-confirmed outcome, clinical case definitions for recruitment of patients can vary. We used the 2022-23 VEBIS primary...
9.
Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study
Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al.
Influenza Other Respir Viruses . 2024 Apr; 18(4):e13292. PMID: 38654485
Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during...
10.
BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study
Musa S, Merdrignac L, Skocibusic S, Nedic R, Cilovic-Lagarija S, Kissling E
Vaccine . 2024 Apr; 42(15):3467-3473. PMID: 38644077
COVID-19 vaccine uptake in the Federation of Bosnia and Herzegovina (FBiH) accelerated in the second half of 2021, with greater vaccine availability. In this study, we estimated the vaccine effectiveness...